Download here the BeBeez Venture 2024 Capital Report available for the subscribers to BeBeez News Premium and BeBeez Private Data.
German nuclear energy startup Proxima Fusion secured a Series A round of 130 million euros from Cherry Ventures, Balderton Capital (lead investors), UVC Partners, DTCF | DeepTech & Climate Fonds, Plural, Leitmotif, Lightspeed, Bayern Kapital, HTGF | High-Tech Gründerfonds, Club degli Investitori, Omnes, Elaia, Visionaries Tomorrow, Wilbe, redalpine, and Max-Planck-Förderstiftung (see here a previous post by BeBeez). Francesco Sciortino (ceo), Lucio Milanese (coo), Andrea Merlo, Martin Kubie, Jorrit Lion, and Jonathan Schilling founded Proxima in 2023 as a spin-out of Max Planck Institute for Plasma Physics (IPP). Sciortino said that the company will invest such proceeds in its organic growth and proprietary technology. Filip Dames is a founder of Cherry Ventures. Daniel Waterhouse is a partner of Balderton Capital. BeBeez Private Data, the private capital database of BeBeez and FSI, monitors Proxima and its investors. Find out here how to subscribe for one month or one year or Click here for booking a demo videocall with BeBeez database manager.
Enterome, a French clinical-stage biopharmaceutical company that is developing OncoMimics first-in-class immunotherapies for cancer treatment, raised 19 million US Dollars from lead investor Institute for Follicular Lymphoma Innovation (9 million), Primo Capital, SymBiosis, Seventure Partners, Lundbeckfonden BioCapital, Therapy Acceleration Program ofa Leukemia & Lymphoma Society (LLS TAP), and its other current shareholders (see here a previous post by BeBeez). The firm will invest the raised proceeds in developing its clinical programme EO2463 for the treatment of indolent non-Hodgkin’s lymphoma (iNHL).
Elkedonia, a French-Belgian biotech startup that is developing a novel neuroplastogen for the treatment of drug-resistant depression and other neuropsychiatric disorders, attracted a seed round of 11.25 million euros from lead investor Kurma Partners, WE Life Sciences (a Wallonia venture investor), French Tech Seed fund, Bpifrance Life Sciences Venture (InnoBio), Argobio, Angelini Industries, Carma Fund, Capital Grand Est, Sambrinvest,and Angelini Ventures, part of Italian pharmaceutical firm (see here a previous post by BeBeez). Elkedonia will invests the raised proceeds in developing a new neuroplastogenic approach that can identify and improve small molecule drug-like molecules that can act on Elk1, a new intracellular target that until now was impossible to treat. BeBeez Private Data, the private capital database of BeBeez and FSI, monitors Angelini Ventures and its Italian portfolio companies. Find out here how to subscribe for one month or one year or Click here for booking a demo videocall with BeBeez database manager
Lionhealth closed a 3 million euros investment round structured in the form of a SAFE (Simple Agreement for Future Equity) (see here a previous post by BeBeez). Vikivi, the holding company of Lionhealth’s founder Paola Lanati, Doorway platform, which raised more than 0.6 million in club deals from over 50 community investors, Lenny Delligatti, and Emilbanca led the round. Riccardo Ballerini, Claudia Benelli, Cristian D’Ippolito, Barbara Marini, Giovanni Pedranzini, Linda Vancini and serial investors such as Dario Calogero, Veronica Mariani, Renate König, Luca Fachini, and Massimo Chistolini also invested in the round. LCA Studio Legale supported Lionhealth.
